These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Off-label use of drugs in psychiatry and neurology]. Wallesch CW Fortschr Neurol Psychiatr; 2004 May; 72(5):243-4. PubMed ID: 15136944 [No Abstract] [Full Text] [Related]
4. [Discussions on the crisis in psychiatry--comments on the paper by Bertalan Pethô]. Kovács J; Botond G; Molnár L; Deák D Psychiatr Hung; 2009; 24(6):439-63. PubMed ID: 20480960 [No Abstract] [Full Text] [Related]
5. Psychiatry in selected countries of Central and Eastern Europe: an overview of the current situation. Füredi J; Mohr P; Swingler D; Bitter I; Gheorghe MD; Hotujac L; Jarema M; Kocmur M; Koychev GI; Mosolov SN; Pecenak J; Rybakowski J; Svestka J; Sartorius N Acta Psychiatr Scand; 2006 Oct; 114(4):223-31. PubMed ID: 16968359 [TBL] [Abstract][Full Text] [Related]
6. [Alarm in Hungarian psychiatry and clinical psychopharmacology]. Gaszner P Neuropsychopharmacol Hung; 2007 Jun; 9(2):49-50. PubMed ID: 17970526 [No Abstract] [Full Text] [Related]
7. [Generics in psychiatry--do they have the same therapeutic equivalence as the original?]. Kasper S; Lentner S Neuropsychiatr; 2008; 22(4):221-2. PubMed ID: 19080992 [No Abstract] [Full Text] [Related]
9. [Competency and responsibility]. Kovács G Neuropsychopharmacol Hung; 2006 Oct; 8(3):101-2. PubMed ID: 17211045 [No Abstract] [Full Text] [Related]
10. Letter by Tracey regarding article, "Bypassing big pharma". Tracey WR Circulation; 2008 Mar; 117(11):e194; author reply e195. PubMed ID: 18347216 [No Abstract] [Full Text] [Related]
11. [Off-label use in psychiatry]. Weih M; Thürauf N; Bleich S; Kornhuber J Fortschr Neurol Psychiatr; 2008 Jan; 76(1):7-13. PubMed ID: 17899492 [TBL] [Abstract][Full Text] [Related]
12. Ethics. Senate probe of research psychiatrists. Kaiser J Science; 2009 Jul; 325(5936):30. PubMed ID: 19574367 [No Abstract] [Full Text] [Related]
13. [Guiding principles for the interpretation of reimbursement categories applicable in definite indications of psychiatric drugs]. Bánki CM Psychiatr Hung; 2007; 22(1):82-8. PubMed ID: 17642122 [No Abstract] [Full Text] [Related]
14. England's new research funding system leaves some fields of psychiatry out in cold. Mayor S BMJ; 2007 Apr; 334(7598):821. PubMed ID: 17446601 [No Abstract] [Full Text] [Related]
15. Regulating new psychoactive drugs: innovation leading to compromise. Schep LJ; Gee P; Tingle M; Galea S; Newcombe D BMJ; 2014 Aug; 349():g5085. PubMed ID: 25122194 [No Abstract] [Full Text] [Related]
17. Irrational fixed dose combinations of psychotropic drugs in India: Cause of concern. Solanki MS; Banwari G Indian J Pharmacol; 2016; 48(4):468-469. PubMed ID: 27756968 [No Abstract] [Full Text] [Related]
18. Expanded access to Phase II clinical trials in oncology: a step toward increasing scientific validity and compassion. Marcee AK Food Drug Law J; 2008; 63(2):439-57. PubMed ID: 18561471 [No Abstract] [Full Text] [Related]
20. The long arm of financial conflicts of interest: extensions into lined pockets, research and review, and the United States Senate. Rivkees SA J Pediatr Endocrinol Metab; 2008 Jul; 21(7):607-9. PubMed ID: 18780592 [No Abstract] [Full Text] [Related] [Next] [New Search]